Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - Gamma Communications Plc
-
Man Group PLC : Form 8.3 - Rotork plc
-
Man Group PLC : Form 8.3 - Sthree plc
-
Man Group PLC : Form 8.3 - Vesuvius Plc
-
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
-
Form 8.5 (EPT/RI)-Tribal Group Plc
-
Transaction in Own Shares
-
Form 8.5 (EPT/RI)-SThree plc
-
Bivial AG Brings Its Complete Dashboard to Mobile
-
Form 8.5 (EPT/RI)-Gamma Communications Plc
-
Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc
-
Notice of 2026 Third Quarter Results Conference Call and Webcast for Analysts and Investors
-
MOBIA Announces New Ownership and Next Chapter of Growth
-
HealthForce Kentucky to Share Its Immersive Health Science Model at NCHSE 2026
-
Morrisons Selects Logile to Enhance Store Planning Across its Supermarket, Convenience and Logistics Sites
-
Friendly Technologies Showcases Faster AI-Assisted Wi-Fi Problem Resolution at Network X, October 13–15, 2026
-
Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC - 13 10 2026 - (CGWL)
-
The Future of Work Social Mixer and Open Demos Draws 300+ Founders, Investors and HR Leaders in San Francisco
-
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
-
seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases
-
Classiq and FreeYa Mind Campus Partner to Establish a Quantum Applications Hub in Romania
-
Zema Global and SatYield bring satellite-based crop intelligence to agricultural commodity markets
-
Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development
-
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
-
WasabiCard and Lotus Tech Explored Enterprise-Driven Stablecoin Payment Use Cases During TOKEN2049 Singapore
-
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
-
OMODA 5 NEXT Makes European Debut, Bringing Avant-Garde Design and Comfort to a New LOHAS Lifestyle
-
The OMODA Family Shines at the 2026 Paris Motor Show: Two Model Debuts Showcase Individuality and Style, Opening a New Chapter in Europe
-
BE THE ONE: OMODA 4 Breaks Boundaries with Its Paris Motor Show Debut
-
Advantest Announces Call for Papers for VOICE 2027 Developer Conference in San Jose, Calif.
-
HERE Technologies expands access to HERE Location Reasoning (HLR), delivering geospatial intelligence for real-world AI with AWS
-
AISLE’s AI Security Platform Accounts for 75% of CVEs in Latest cURL Release
-
Vattenfall Awards 1 GWh Brunsbüttel Battery Storage Project to Fluence
-
Nouryon highlights its biocides portfolio as regulations reshape disinfectant choices
-
Regula Identity Verification Platform Wins 2026 Merit Technology Award
-
Karri Alameri will leave his position as Chief Executive Officer of Oma Savings Bank Plc
-
IE Business School Turns ABB Bank’s Transformation Journey into a Case-study
-
Notice of the Extraordinary General Meeting of Oma Savings Bank Plc
-
Quadient Expands Agentic AI to Accounts Receivable, Turning Customer Emails into Action
-
NVIDIA Commits $250 Million to Advance UK Agentic Safety and Security Research Over the Next Five Years
-
VodafoneZiggo Receives EU Commission Clearance For Tower Sale
-
FORVIA strengthens AI leadership with the appointment of Raphaël Viard to the Executive Committee
-
FORVIA appoints Olivier Lefebvre Head of the JIKA (Japan, India, Korea, ASEAN) Region
-
Pulsar Helium and Lunar Helium-3 Mining Sign Evaluation Agreement for Helium-3 Recovery Assessment at Topaz
-
Shield Appoints Michelle Clark as Global Communications Surveillance Expert to Strengthen Product Strategy and Customer Programs
-
Crypto Marketing Agency ICODA Launches Brand Protection Service Against Clone Sites
-
Changes in Marimekko’s management
-
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
-
Director/PDMR Shareholding
-
NBPE Announces Transaction in Own Shares
